There are 2789 resources available
155P - The addition of pyrotinib in early or locally advanced HER2-positive breast cancer patients with no response to two cycles of neoadjuvant therapy: A prospective, multicenter study
Presenter: zhi gang YU
Session: ePoster Display
156P - Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
Presenter: Camille Domergue
Session: ePoster Display
157P - Moderate physical activity (MPA) modulates immune system in breast cancer (BC) patients during preoperative chemotherapy: The NEO-RUNNER study
Presenter: Ornella Garrone
Session: ePoster Display
158P - Prognosis of pregnancy after breast cancer diagnosis according to the treatment
Presenter: Sungmin Park
Session: ePoster Display
159P - SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers
Presenter: Jacqueline Lehmann-Che
Session: ePoster Display
161P - Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
Presenter: David Veenstra
Session: ePoster Display
81P - Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)
Presenter: Javier Garcia-Corbacho
Session: ePoster Display
49P - A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
Presenter: Nai-Jung Chiang
Session: ePoster Display
1823P - Differential mutational landscape of duodenal carcinomas: A real-world data analysis from the GENIE Consortium Cohort
Presenter: Italo Fernandes
Session: ePoster Display